PEPTIDE WITH PUTATIVE ROLE IN CYTOSKELETAL PROTECTION

• US 20070167366A1
• Filed: 12/12/2006
• Published: 07/19/2007
• Est. Priority Date: 12/12/2005
• Status: Active Grant

• Current Assignee: Mohsen Amin, Richard Ellen
• Original Assignee: Mohsen Amin, Richard Ellen
• Inventors: Amin, Mohsen, Ellen, Richard
• Granted Patent: US 7,659,366 B2
• Time in Patent Office: Days
• US Class Current: 530/328
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 7/06 having 5 to 11 amino acids

Abstract

The invention relates to a novel peptide conjugate useful for stabilizing the actin cytoskeleton of mammalian cells. More particularly, the invention relates to a conjugate of a peptide found within the sequence of a bacterium'"'"'s major outer sheath protein and bovine serum albumin (BSA), and the use of this conjugate for stabilizing the actin cytoskeleton of mammalian cells, and for preventing or controlling the migration of mammalian cells.

Claims

1. A peptide conjugate comprising a carrier and at least one peptide, wherein said at least one peptide has the peptide sequence YAGXDXNNXA, and X is a positively charged amino acid residue.

2. The peptide conjugate as claimed in claim 1, wherein X is a lysine residue.

3. The peptide conjugate as claimed in claim 1 or 2, wherein the carrier is bovine serum albumin.

4. The peptide conjugate as claimed in claim 3, wherein said conjugate comprises 6 peptides.

5. Use of the peptide conjugate as claimed in claim 1 or 2 for stabilizing the actin cytoskeleton of mammalian cells.

6. The use as claimed in claim 5, wherein said mammalian cells are fibroblast cells.

7. A method for preventing or controlling migration of mammalian cells, comprising the step of exposing said mammalian cells to the peptide conjugate as claimed in claim 1 or 2.

8. The method as claimed in claim 7, wherein said mammalian cells are fibroblast cells.

9. The method as claimed in claim 7, wherein said mammalian cells are neutrophils.

10. The method as claimed in claim 7, wherein the peptide conjugate is present in a concentration of about 50 μ

g/ml.